Best Paper Award

4.4Impact Factor
8.8CiteScore
21 daysTime to First Decision

Cancers Best Paper Award is granted annually to highlight publications of high quality, scientific significance, and extensive influence. The evaluation committee members choose four articles of exceptional quality that were published in the journal in the previous year and announce them online by the end of June.

The Prize:
– Two research articles and two reviews will be selected.
– Each winner will receive CHF 500, a certificate, and a chance to publish a paper free of charge in Cancers before the end of June 2027 after peer review.

Cancers Best Paper Award

Winner announcement date: 30 June 2026

Eligibility and Requirements

– All papers published in Cancers will be eligible (both regular and Special Issue submissions).

Selection Criteria

– Scientific merit and broad impact;
– Originality of the research objectives and/or the ideas presented;
– Creativity of the study design or uniqueness of the approaches and concepts;
– Clarity of presentation;
– Citations and downloads.

Past Winners

Winner

Article
11 Citations
24,317 Views
13 Pages
Download PDF
Circulating Chromosome Conformation Signatures Significantly Enhance PSA Positive Predicting Value and Overall Accuracy for Prostate Cancer Detection
Dmitri Pchejetski,
Ewan Hunter,
Mehrnoush Dezfouli,
Matthew Salter,
Ryan Powell,
Jayne Green,
Tarun Naithani,
Christina Koutsothanasi,
Heba Alshaker and
Jiten Jaipuria
+ 6 authors
Cancers2023, 15(3), 821;https://doi.org/10.3390/cancers15030821
-
29 January 2023
Background: Prostate cancer (PCa) has a high lifetime prevalence (one out of six men), but currently there is no widely accepted screening programme. Widely used prostate specific antigen (PSA) test at cut-off of 3.0 ng/mL does not have sufficient ac...
Full Article
Article
14 Citations
12,672 Views
16 Pages
Download PDF
Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study
Jennifer A. Woyach,
Paul M. Barr,
Thomas J. Kipps,
Jacqueline C. Barrientos,
Inhye E. Ahn,
Paolo Ghia,
Vincent Girardi,
Emily Hsu,
Mandy Jermain and
Jan A. Burger
Cancers2023, 15(2), 507;https://doi.org/10.3390/cancers15020507
-
13 January 2023
Primary results from the phase 3 RESONATE-2 study demonstrated superior efficacy and tolerability with ibrutinib versus chlorambucil in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Here, we describe characteristi...
Full Article
Review
251 Citations
35,199 Views
35 Pages
Download PDF
Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
Toan D. Nguyen,
Brandon M. Bordeau and
Joseph P. Balthasar
Cancers2023, 15(3), 713;https://doi.org/10.3390/cancers15030713
-
24 January 2023
Anti-cancer antibody-drug conjugates (ADCs) aim to expand the therapeutic index of traditional chemotherapy by employing the targeting specificity of monoclonal antibodies (mAbs) to increase the efficiency of the delivery of potent cytotoxic agents t...
Full Article
Review
98 Citations
27,490 Views
53 Pages
Download PDF
What Is Known about Breast Cancer in Young Women?
Jie Wei Zhu,
Parsa Charkhchi,
Shadia Adekunte and
Mohammad R. Akbari
Cancers2023, 15(6), 1917;https://doi.org/10.3390/cancers15061917
-
22 March 2023
Breast cancer (BC) is the second leading cause of cancer-related death in women under the age of 40 years worldwide. In addition, the incidence of breast cancer in young women (BCYW) has been rising. Young women are not the focus of screening program...
Full Article

Award Committee

Samuel Mok
Samuel Mok
Chairman
UT MD Anderson Cancer Center
Jochen Utikal
Jochen Utikal
German Cancer Research Center/ University of Heidelberg
Gabriele Multhoff
Gabriele Multhoff
TranslaTUM
Avraham Eisbruch
Avraham Eisbruch
University of Michigan
Dania Cioni
Dania Cioni
University of Pisa
Ada Funaro
Ada Funaro
Deparment of Medical Sciences, University of Torino, Italy
Alessandro Pileri
Alessandro Pileri
Benjamin Bonavida
Benjamin Bonavida
Carlos Moreno
Carlos Moreno
Emory University
Alan Hutson
Alan Hutson
Roswell Park Comprehensive Cancer Center